Vol 15, No 1 (2020)
Review paper
Published online: 2020-02-28
A fresh perspective on anticoagulant therapy in patients with cancer in the era of NOAC
Folia Cardiologica 2020;15(1):27-33.
Abstract
Cancer is a condition associated with hypercoagulability requiring anticoagulant therapy. In recent years, oncological patients have been given heparin and vitamin K antagonists. Nowadays, non-vitamin K antagonist oral anticoagulants (NOAC) are becoming increasingly widely used. Based on the current state of knowledge, NOAC drugs can be used in anticoagulant treatment of cancer patients with caution, i.e. after assessing the bleeding risk and a risk-benefit analysis of anticoagulant therapy, as well as of the drug interactions between oncological drugs and the NOAC group.
Keywords: canceranticoagulant treatmentnon-vitamin K antagonist oral anticoagulants